These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9285690

  • 1. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
    Ueno NT, Yu D, Hung MC.
    Oncogene; 1997 Aug 18; 15(8):953-60. PubMed ID: 9285690
    [Abstract] [Full Text] [Related]

  • 2. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC.
    Clin Cancer Res; 2000 Jan 18; 6(1):250-9. PubMed ID: 10656456
    [Abstract] [Full Text] [Related]

  • 3. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 4. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H, Qin H, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2000 Sep 06; 22(5):370-3. PubMed ID: 11778270
    [Abstract] [Full Text] [Related]

  • 5. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y, Zou YY, Xia WY, Hung MC.
    Cancer Gene Ther; 2004 Sep 06; 11(9):594-602. PubMed ID: 15272313
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY, Xia W, Shao R, Hung MC.
    Oncogene; 1996 Oct 03; 13(7):1405-12. PubMed ID: 8875978
    [Abstract] [Full Text] [Related]

  • 7. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
    Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC.
    Cancer Res; 2002 Nov 15; 62(22):6712-6. PubMed ID: 12438271
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
    Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC.
    Oncogene; 1996 Sep 19; 13(6):1359-65. PubMed ID: 8808711
    [Abstract] [Full Text] [Related]

  • 9. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC.
    Oncogene; 1995 Oct 05; 11(7):1383-8. PubMed ID: 7478560
    [Abstract] [Full Text] [Related]

  • 10. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y, Yu D, Xia W, Hung MC.
    Oncogene; 1995 May 18; 10(10):1947-54. PubMed ID: 7761095
    [Abstract] [Full Text] [Related]

  • 11. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 1999 Feb 18; 5(2):343-53. PubMed ID: 10037184
    [Abstract] [Full Text] [Related]

  • 12. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 13. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
    Zhou Z, Jia SF, Hung MC, Kleinerman ES.
    Cancer Res; 2001 Apr 15; 61(8):3394-8. PubMed ID: 11309298
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
    Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL.
    Clin Cancer Res; 2001 May 15; 7(5):1237-45. PubMed ID: 11350889
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr 15; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 16. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.
    J Surg Res; 2006 May 15; 132(2):208-13. PubMed ID: 16580691
    [Abstract] [Full Text] [Related]

  • 17. [Effect of E1A gene on in vitro growth inhibition and radiochemosensitivity of lymph node metastasis cells of human head and neck squamous cell carcinoma].
    Wang XL, Qian XL, Zhao QZ, Xu ZG, Tang PZ.
    Ai Zheng; 2003 Nov 15; 22(11):1140-6. PubMed ID: 14613640
    [Abstract] [Full Text] [Related]

  • 18. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ.
    Oncogene; 1997 Jul 31; 15(5):537-47. PubMed ID: 9247307
    [Abstract] [Full Text] [Related]

  • 19. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT.
    Gene Ther; 1997 Apr 31; 4(4):317-22. PubMed ID: 9176517
    [Abstract] [Full Text] [Related]

  • 20. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
    Wagner JA.
    Curr Opin Mol Ther; 1999 Apr 31; 1(2):266-70. PubMed ID: 11715950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.